Randall G. Rupp
Nessuna posizione attualmente
Profilo
Randall G.
Rupp served as Director-Cell Biology at Damon Biotech, Inc. He then worked at Regeneron Pharmaceuticals, Inc. for 17 years, where he held the position of Senior Vice President-Manufacturing Operations.
After leaving Regeneron, he worked as Vice President-Manufacturing & Development at Noveome Biotherapeutics, Inc. and as Vice President-Research & Development at BioHybrid Technologies, Inc. Rupp holds a doctorate degree from The University of Texas at Austin.
Precedenti posizioni note di Randall G. Rupp
| Società | Posizione | Fine |
|---|---|---|
| REGENERON PHARMACEUTICALS, INC. | Corporate Officer/Principal | 02/04/2008 |
| Damon Biotech, Inc. | Corporate Officer/Principal | - |
| BioHybrid Technologies, Inc. | Direttore Tecnico/Scientifico/R&S | - |
Noveome Biotherapeutics, Inc.
 Noveome Biotherapeutics, Inc. BiotechnologyHealth Technology Noveome Biotherapeutics, Inc. develops novel biotherapeutic products that restore cell communication and system homeostasis. Its proprietary technology platform, derived from human placental cells, provides an exciting new approach to tissue regeneration and repair in a wide range of medical conditions and offers hope, especially in patients with maladies. The company was founded in 2001 by George L. Sing and William J. Golden and is headquartered in Pittsburgh, PA. | Corporate Officer/Principal | - |
Formazione di Randall G. Rupp
| The University of Texas at Austin | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| REGENERON PHARMACEUTICALS, INC. | Health Technology |
| Aziende private | 3 |
|---|---|
Noveome Biotherapeutics, Inc.
Noveome Biotherapeutics, Inc. BiotechnologyHealth Technology Noveome Biotherapeutics, Inc. develops novel biotherapeutic products that restore cell communication and system homeostasis. Its proprietary technology platform, derived from human placental cells, provides an exciting new approach to tissue regeneration and repair in a wide range of medical conditions and offers hope, especially in patients with maladies. The company was founded in 2001 by George L. Sing and William J. Golden and is headquartered in Pittsburgh, PA. | Health Technology |
| BioHybrid Technologies, Inc. | |
| Damon Biotech, Inc. | Health Technology |
- Borsa valori
- Insiders
- Randall G. Rupp
